4 235

Cited 48 times in

Chemotherapy use and associated factors among cancer patients near the end of life

Authors
 Young Ho Yun  ;  Miyoung Kwak  ;  Dae Seog Heo  ;  Si-Young Kim  ;  Young Seon Hong  ;  Youn Seon Choi  ;  Chang Geol Lee  ;  Ho-Yeong Lim  ;  Jong Soo Choi  ;  Samyong Kim  ;  Sang Min Park 
Citation
 ONCOLOGY, Vol.72(3-4) : 164-171, 2007 
Journal Title
 ONCOLOGY 
ISSN
 0030-2414 
Issue Date
2007
Abstract
OBJECTIVES: We investigated the frequency of chemotherapy use and its associated factors in patients in all age groups in the last year of life. METHODS: We identified cancer patients who died in 2004 in any of 17 hospitals. We used demographic and treatment characteristics by computerized hospital information systems and by linking the identification numbers to the 2004 death registry. RESULTS: 48.7% of patients in the last 6 months of life, 43.9% in the last 3 months, and 30.9% in the last month of life received chemotherapy. The frequency of chemotherapy use was lower for older patients. In those > or =65 years old, there was no difference between women and men in the proportion that received chemotherapy. For patients <65 years of age, a larger proportion of women than men received chemotherapy, and chemotherapy use was significantly less frequent for patients with refractory disease than for those with responsive disease. Patients dying at a relatively small hospital without a hospice inpatient unit were significantly more likely to receive chemotherapy. CONCLUSIONS: Despite the fact that most cancer patients are resistant to chemotherapy at the end of life, it was administered often to all age groups.
Full Text
http://www.karger.com/Article/FullText/112802
DOI
10.1159/000112802
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
Yonsei Authors
Lee, Chang Geol(이창걸) ORCID logo https://orcid.org/0000-0002-8702-881X
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/97224
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links